Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/23/2026, 12:00:00 AM
Announced fiscal year 2025 results on 2026-03-23, reporting revenue of RMB 2.06 billion (+6.5%) and a net loss of RMB 382 million (+43.2%); High importance estimated due to significant loss widening expected.
Korean Translation
2026년 3월 23일 2025년 회계연도 실적 발표. 매출 20.6억 위안(6.5% 증가) 및 순손실 3.82억 위안(43.2% 확대)에 따른 큰 폭의 주가 영향으로 높은 중요도 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM